.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XK04_Talazoparib.Talazoparib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XK04_Talazoparib.Talazoparib| name: | Talazoparib |
| ATC code: | L01XK04 | route: | oral |
| n-compartments | 2 |
Talazoparib is an orally administered poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. It is currently approved for medical use.
Pharmacokinetic parameters in adult patients with cancer following oral administration.
Yu, Y, et al., & Wang, DD (2020). Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer. Journal of clinical pharmacology 60(2) 218–228. DOI:10.1002/jcph.1520 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31489639
Hoy, SM (2018). Talazoparib: First Global Approval. Drugs 78(18) 1939–1946. DOI:10.1007/s40265-018-1026-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/30506138
Luo, Y, et al., & Xu, B (2023). Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors. Investigational new drugs 41(3) 503–511. DOI:10.1007/s10637-023-01351-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/37171721